BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program

Contributed by: PR Newswire

Tags

BIOARCTIC

More Like This

BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing

BioArctic and Eisai sign research evaluation agreement regarding BAN2802

BrainTransporter™ dramatically improves antibody delivery to the brain

BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress

BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress

PR Newswire associated0

ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases

The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association

Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic